NeuroOne Wins FDA Clearance for Facial Pain Device
NeuroOne Medical Technologies received FDA clearance for its OneRF ablation system to treat trigeminal neuralgia, a chronic facial pain condition affecting about 150,000 Americans annually. The minimally invasive device uses radiofrequency energy to create lesions that interrupt pain signals from the trigeminal nerve. The Eden Prairie, Minnesota-based company plans a limited launch in Q4 2024, marking its first expansion into chronic pain treatment beyond neurosurgery applications. CEO Dave Rosa said the company expects to pursue additional pain management opportunities, including lower back pain treatments, leveraging its technology platform.
Posted by MedCloudInsider Editors on 08/20/2025